Analyst Emily Bodnar from H.C. Wainwright maintained a Buy rating on RAPT Therapeutics and keeping the price target at $72.00.
Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Emily Bodnar’s rating is based on the promising potential of RAPT Therapeutics’ lead candidate, ozureprubart, which has shown a significantly longer half-life compared to omalizumab, potentially allowing for less frequent dosing. The Phase 2 trial results in chronic spontaneous urticaria (CSU) demonstrated promising efficacy, with a higher percentage of complete response scores compared to omalizumab, suggesting superior efficacy with less frequent dosing.
Additionally, the company is preparing for a Phase 3 trial, with the possibility of accelerated approval due to recent FDA guidance. The upcoming asthma data readout and the initiation of a new trial in food allergy further bolster the company’s pipeline, making RAPT a compelling investment opportunity.